High levels of antibiotic resistance found worldwide, new data shows



WHO’s first launch of surveillance information on antibiotic resistance reveals excessive ranges of resistance to a variety of critical bacterial infections in each high- and low-income international locations.

WHO’s new Global Antimicrobial Surveillance System (GLASS) reveals widespread prevalence of antibiotic resistance amongst 500 000 individuals with suspected bacterial infections throughout 22 international locations.

The mostly reported resistant micro organism have been Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pneumoniae, adopted by Salmonella spp. The system doesn’t embrace information on resistance of Mycobacterium tuberculosis, which causes tuberculosis (TB), as WHO has been monitoring it since 1994 and offering annual updates within the Global tuberculosis report.

Among sufferers with suspected bloodstream an infection, the proportion that had micro organism proof against a minimum of probably the most generally used antibiotics ranged tremendously between completely different international locations – from zero to 82%. Resistance to penicillin – the drugs used for many years worldwide to deal with pneumonia – ranged from zero to 51% amongst reporting international locations. And between eight% to 65% of E. coli related to urinary tract infections offered resistance to ciprofloxacin, an antibiotic generally used to deal with this situation.

“The report confirms the serious situation of antibiotic resistance worldwide,” says Dr Marc Sprenger, director of WHO’s Antimicrobial Resistance Secretariat.

“Some of the world’s most common – and potentially most dangerous – infections are proving drug-resistant,” provides Sprenger. “And most worrying of all, pathogens don’t respect national borders. That’s why WHO is encouraging all countries to set up good surveillance systems for detecting drug resistance that can provide data to this global system.”

To date, 52 international locations (25 high-income, 20 middle-income and seven low-income international locations) are enrolled in WHO’s Global Antimicrobial Surveillance System. For the primary report, 40 international locations offered details about their nationwide surveillance programs and 22 international locations additionally offered information on ranges of antibiotic resistance.

“The report is a vital first step towards improving our understanding of the extent of antimicrobial resistance. Surveillance is in its infancy, but it is vital to develop it if we are to anticipate and tackle one of the biggest threats to global public health,” says Dr Carmem Pessoa-Silva, who coordinates the brand new surveillance system at WHO.

Data offered on this first GLASS report differ broadly in high quality and completeness. Some international locations face main challenges in constructing their nationwide surveillance programs, together with an absence of personnel, funds and infrastructure.

However, WHO is supporting extra international locations to arrange nationwide antimicrobial resistance surveillance programs that may produce dependable, significant information. GLASS helps to standardize the way in which that international locations accumulate information and allow a extra full image about antimicrobial resistance patterns and tendencies.

Solid drug resistance surveillance programmes in TB, HIV and malaria have been functioning for a few years and have helped estimate illness burden, plan diagnostic and therapy companies, monitor the effectiveness of management interventions, and design efficient therapy regimens to handle and forestall future resistance. GLASS is predicted to carry out the same perform for frequent bacterial pathogens.

The rollout of GLASS is already making a distinction in lots of international locations. For instance, Kenya has enhanced the event of its nationwide antimicrobial resistance system; Tunisia began to mixture information on antimicrobial resistance at nationwide stage; the Republic of Korea fully revised its nationwide surveillance system to align with the GLASS methodology, offering information of very prime quality and completeness; and international locations similar to Afghanistan or Cambodia that face main structural challenges have enrolled within the system and are utilizing the GLASS framework as a possibility for strengthening their AMR surveillance capacities. In common, nationwide participation in GLASS is seen as an indication of rising political dedication to help international efforts to regulate antimicrobial resistance.

Note to editors

The want for a world surveillance system was highlighted by WHO in 2014 within the Antimicrobial resistance international report on surveillance.

In October 2015, WHO launched the Global Antimicrobial Surveillance System (GLASS) working carefully with WHO Collaborating Centres and current antimicrobial resistance surveillance networks and primarily based on the expertise of different WHO surveillance programmes. For instance, TB drug resistance surveillance has been applied in 188 international locations over the previous 24 years. HIV drug resistance surveillance began in 2005 and by 2017, over 50 international locations had reported information on pretreatment and purchased resistance utilizing standardized survey strategies.

Any nation, at any stage of the event of its nationwide antimicrobial resistance surveillance system, can enrol in GLASS. Countries are inspired to implement the surveillance requirements and indicators regularly, primarily based on their nationwide priorities and accessible assets.

GLASS will finally incorporate info from different surveillance programs associated to antimicrobial resistance in people, similar to within the meals chain, monitoring of antimicrobial consumption, focused surveillance initiatives, and different associated information.

All information produced by GLASS is obtainable free on-line and might be up to date usually.

Dr Tedros Adhanom Ghebreyesus, WHO’s Director-General, has underscored his intention to make antimicrobial resistance one in every of WHO’s prime priorities by bringing collectively consultants engaged on this situation below a newly created strategic initiatives cluster.

Media contact:

Christian Lindmeier
Telephone: +41 22 791 1948
Mobile: +41 79 500 6552
Email: lindmeierch@who.int



Source link

Reply